These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31129911)

  • 61. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
    Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
    Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).
    Park SD; Lee MJ; Baek YS; Kwon SW; Shin SH; Woo SI; Kim DH; Kwan J; Park KS
    EuroIntervention; 2016 Oct; 12(8):e964-e971. PubMed ID: 27721212
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
    Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
    Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Microvascular dysfunction determines infarct characteristics in patients with reperfused ST-segment elevation myocardial infarction: The MICROcirculation in Acute Myocardial Infarction (MICRO-AMI) study.
    McAlindon E; Pufulete M; Harris J; Lawton C; Johnson T; Strange J; Baumbach A; Bucciarelli-Ducci C
    PLoS One; 2018; 13(11):e0203750. PubMed ID: 30422990
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.
    Fokkema ML; Vlaar PJ; Vogelzang M; Gu YL; Kampinga MA; de Smet BJ; Jessurun GA; Anthonio RL; van den Heuvel AF; Tan ES; Zijlstra F
    Circ Cardiovasc Interv; 2009 Aug; 2(4):323-9. PubMed ID: 20031735
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA;
    Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
    Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
    Hideo-Kajita A; Rogers T; Buchanan K; Iantorno M; Gajanana D; Ozaki Y; Dan K; Kolm P; Brathwaite E; Beyene S; Melaku G; Meirovich Y; Dheendsa A; Garcia-Garcia HM; Torguson R; Waksman R
    Am J Cardiol; 2019 Apr; 123(8):1228-1238. PubMed ID: 30738570
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
    Xu J; Lo S; Mussap CJ; French JK; Rajaratnam R; Kadappu K; Premawardhana U; Nguyen P; Juergens CP; Leung DY
    Circ Cardiovasc Interv; 2022 Apr; 15(4):e011419. PubMed ID: 35369712
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction).
    Thiele H; Eitel I; Meinberg C; Desch S; Leuschner A; Pfeiffer D; Hartmann A; Lotze U; Strauss W; Schuler G;
    JACC Cardiovasc Interv; 2011 Jun; 4(6):605-14. PubMed ID: 21700245
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antithrombotic Stewardship: Evaluation of Platelet Reactivity-Guided Cangrelor Dosing Using the VerifyNow Assay.
    Connery A; Ahuja T; Katz A; Arnouk S; Zhu E; Papadopoulos J; Rao S; Merchan C
    J Cardiovasc Pharmacol; 2024 May; 83(5):482-489. PubMed ID: 38335531
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
    De Backer O; Ratcovich H; Biasco L; Pedersen F; Helqvist S; Saunamäki K; Tilsted HH; Clemmensen P; Olivecrona G; Kelbaek H; Jørgensen E; Engstrøm T; Holmvang L
    Thromb Haemost; 2015 Aug; 114(3):623-31. PubMed ID: 25994355
    [TBL] [Abstract][Full Text] [Related]  

  • 76. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
    Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G
    Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    Montalescot G; van 't Hof AW; Lapostolle F; Silvain J; Lassen JF; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Stibbe O; Ecollan P; Heutz WM; Swahn E; Collet JP; Willems FF; Baradat C; Licour M; Tsatsaris A; Vicaut E; Hamm CW;
    N Engl J Med; 2014 Sep; 371(11):1016-27. PubMed ID: 25175921
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
    Tavenier AH; Hermanides RS; Ottervanger JP; Tolsma R; van Beurden A; Slingerland RJ; Ter Horst PGJ; Gosselink ATM; Dambrink JE; van Leeuwen MAH; Roolvink V; Kedhi E; Klungel OH; Belitser SV; Angiolillo DJ; Pustjens T; Rasoul S; Gho B; Stein M; Ruiters L; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Jan; 8(1):4-12. PubMed ID: 32730628
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.